Results 241 to 250 of about 405,156 (331)

A Proof‐of‐Concept Phase 2a Partly Randomised Study Evaluating Leronlimab in Patients With Presumed Non‐Cirrhotic Metabolic Dysfunction–Associated Steatohepatitis

Liver International Communications, Volume 6, Issue 4, December 2025.
ABSTRACT Chemokine receptor type 5 (CCR5) is upregulated in the livers of patients with metabolic dysfunction–associated steatohepatitis (MASH). Leronlimab, a humanised IgG4κ monoclonal antibody, directly binds the extracellular domains of CCR5, modulates downstream signalling and potentially can slow, reverse or prevent fibrosis. The aim of this study
Melissa Palmer, A. Cyrus Arman, Eric J. Lawitz, William E. Sanchez, Shilpi Mittal, Tarek Hassanein, Scott G. Hansen, Joseph Meidling, Bernie Cunningham, Neil E. Buss, Jacob P. Lalezari   +10 more
wiley   +1 more source

Monoclonal antibodies to human IgM

Medical Journal of Indonesia, 1999
Agustin Indrawati, Fera Ibrabim, Mardiastuti Mardiastuti, Agus Sjahrurachman, Betty Ernawati   +4 more
openaire   +3 more sources

Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review. [PDF]

Front Immunol
Kou K, Zhou Q, Du L, Xu F.
europepmc   +1 more source

Breast Cancer Brain Metastasis: Bridging Biological Mechanisms to Therapeutic Innovations

MedComm – Oncology, Volume 4, Issue 4, December 2025.
Breast cancer brain metastasis (BCBrM) is driven by a multistep metastatic cascade and shaped by dynamic tumor–brain interactions. This review integrates current mechanistic insights, from molecular signaling pathways to immune evasion, and evaluates preclinical models and emerging therapies.
Jing Feng, Yuwei Tao, Fengkai Li, Suling Liu   +3 more
wiley   +1 more source

New insights in the immune treatment of Guillain-Barré syndrome. [PDF]

Curr Opin Neurol
Wiegers EJA, Jacobs BC.
europepmc   +1 more source

Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors

Pediatric Blood &Cancer, Volume 72, Issue 12, December 2025.
ABSTRACT Background Combining immune checkpoint inhibitors (ICI) with chemotherapy may improve treatment response in children with solid tumors. We sought to determine the feasibility of combining vincristine, irinotecan, and temozolomide with the ICI atezolizumab in children with relapsed or refractory solid tumors (VITAS;). Methods Patients ≥6 months
Matthew E. Campbell, Sonja Stutzman, Sharon Primeaux, Deseray Sida, Minjae Lee, Avanthi T. Shah, Arhanti Sadanand, Elizabeth Sokol, Natalie B. Collins, Brian Turpin, Shoba Navai, Katie Albert, Theodore W. Laetsch, Dinesh Rakheja, Kenneth S. Chen, David E. Gerber, Andrew Y. Koh   +16 more
wiley   +1 more source

Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy. [PDF]

Transl Oncol
Dalloul Z, Briend JG, Diawara M, Taylor C, Ouellette RJ.   +4 more
europepmc   +1 more source

Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review

Biotechnology and Bioengineering, Volume 122, Issue 11, Page 3229-3248, November 2025.
ABSTRACT Host cell proteins (HCP) are process‐related impurities that can co‐purify with therapeutic proteins. Some HCP impurities potentially can have an impact on patient safety (immunogenicity or toxicity), efficacy, and/or product quality. It is important to reduce the levels of HCP impurities with a well‐controlled manufacturing process and to ...
Lisette Coye, Marisa A. Jones, Georgeen Gaza‐Bulseco, Carmelata Chitikila, Severine Clavier, Delphine Fougeron, Christine Grimaldi, Karen Hurkmans, Richard Hutchinson, Brenda Kellogg, Xinrong Liu, Nisha Palackal, Mahima Tank, Pascal Valax, Thomas Waerner, Fengqiang Wang, Ying Zhang, Yiwei Zhao, Sapphire Sloan, Christina Zuch de Zafra   +19 more
wiley   +1 more source

Heparanase-Neutralizing Monoclonal Antibody (mAb A54) Attenuates Tumor Growth and Metastasis. [PDF]

Cells
Barash U, Farhoud M, Odeh M, Huberman E, Wu L, Vlodavsky I.   +5 more
europepmc   +1 more source

Efficacy and Toxicity of Inotuzumab Ozogamicin for Treatment of Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients After CD19‐Chimeric Antigen Receptor T‐Cell Therapy

Pediatric Blood &Cancer, Volume 72, Issue 11, November 2025.
ABSTRACT We retrospectively analyzed outcomes for nine children and young adults who were treated with inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) B‐acute lymphoblastic leukemia (ALL) after CD19‐chimeric antigen receptor T‐cell therapy (CART).
Paula Ogrodnik, Eric Anderson, Nicholas Gloude, Deborah Schiff   +3 more
wiley   +1 more source